Sequencing Therapy After Osimertinib-Based Treatment in EGFR-Mutant NSCLC

This segment explores treatment sequencing following progression on osimertinib-based therapy for EGFR-mutant non-small cell lung cancer (NSCLC). Drs. Mark Socinski and Susan Scott discuss how frontline treatment selection influences subsequent therapeutic options, emphasizing the importance of ensuring that patients have access to multiple effective therapies throughout their disease course. They review second-line approaches following the FLAURA2 regimen, including platinum-based chemotherapy rechallenge, the MARIPOSA-2 regimen, and datopotamab deruxtecan, while highlighting the need to individualize sequencing based on prior treatment exposure and duration of response. The discussion also examines the evolving role of VEGF-directed therapies, including durable clinical responses observed with VEGF-based regimens and emerging data evaluating novel agents such as ivonescimab. The experts conclude by highlighting the importance of continued disease control, thoughtful sequencing, and ongoing clinical research to expand future treatment options for patients with EGFR-mutant NSCLC.